Alport syndrome is a genetic disorder that damages the kidneys, hearing, and vision. It’s caused by mutations in genes responsible for producing a specific type of collagen, a structural protein that forms the filtering membranes in the kidneys, the inner ear, and the eyes. About 85% of cases are inherited through the X chromosome, which means the condition affects males and females differently. Without treatment, it progressively worsens kidney function and can lead to kidney failure.
What Causes Alport Syndrome
The condition traces back to mutations in three genes: COL4A3, COL4A4, and COL4A5. These genes carry the instructions for building specific chains of type IV collagen, which weave together into a triple-helix structure. That collagen network forms the glomerular basement membrane, a microscopic filter inside the kidneys that separates waste from blood. The same collagen network also supports structures in the inner ear and the eye.
During normal kidney development, the filtering membrane undergoes a maturation process. Early in life, it relies on simpler collagen chains. As the kidney matures, it switches to the more specialized chains encoded by these three genes. In Alport syndrome, that switch either fails or produces defective collagen. The kidney gets stuck using the simpler, fetal version of collagen, which is more vulnerable to damage from the body’s own enzymes. Over time, this causes the membrane to split, thin, and deteriorate. One of the most common types of mutation involves a single amino acid swap in the collagen chain that introduces a kink in the molecule, preventing it from folding correctly.
How It’s Inherited
There are three inheritance patterns, and the most common one, accounting for roughly 85% of cases, is X-linked. This form involves mutations in the COL4A5 gene on the X chromosome. Because males have only one X chromosome, a single copy of the mutation causes the full disease. Males with X-linked Alport syndrome typically develop kidney failure, often by their 20s or 30s. Females carry two X chromosomes, so a working copy on one can partially compensate. Still, female carriers are not simply unaffected. About 15% to 30% of female carriers develop kidney failure by age 60, and many experience hearing loss in middle age.
Autosomal recessive Alport syndrome accounts for another 10% to 15% of cases. It results from mutations in COL4A3 or COL4A4, and a child needs to inherit a defective copy from both parents. This form affects males and females equally. Autosomal dominant Alport syndrome, where a single copy of a COL4A3 or COL4A4 mutation causes disease, is the rarest form and tends to progress more slowly.
Kidney Symptoms and Progression
The earliest sign is blood in the urine, which can appear in childhood. In many cases, the blood is only visible under a microscope. As the filtering membrane deteriorates, protein begins leaking into the urine as well, a sign that the kidneys are losing their ability to retain important molecules. Over years or decades, kidney function declines. The pace depends heavily on the type of mutation, the inheritance pattern, and whether treatment begins early. Some milder mutations cause only blood in the urine and late-onset kidney problems, while more severe mutations can lead to kidney failure in adolescence or early adulthood.
Hearing Loss and Eye Changes
Because the same collagen network supports structures in the inner ear, hearing loss is common. It’s the sensorineural type, meaning it stems from damage to the inner ear rather than a blockage. It typically starts with difficulty hearing high-pitched sounds and worsens over time. In one clinical study, about 63% of patients had some degree of hearing impairment.
Eye involvement occurs in roughly 40% of patients, though it varies. The most distinctive finding is anterior lenticonus, a condition where the front surface of the lens bulges forward. It affects 15% to 20% of patients with X-linked or autosomal recessive Alport syndrome and causes gradual vision changes. People with anterior lenticonus often need frequent updates to their glasses prescriptions, and it can eventually lead to cataracts. Another eye finding is dot-and-fleck retinopathy, an abnormal pigment pattern on the retina. This typically doesn’t affect vision but can help clinicians recognize the syndrome.
How It’s Diagnosed
Diagnosis can be tricky based on symptoms and family history alone, especially in families where no one has been previously identified with the condition. Genetic testing is the most sensitive and accurate method. It can pinpoint the exact mutation and confirm which inheritance pattern is involved, which matters for predicting how the disease will behave and for counseling other family members about their risk.
A kidney biopsy can also provide important clues. Under electron microscopy, the glomerular basement membrane shows a characteristic pattern of splitting and layering (called lamellation) or diffuse thinning. Very few other conditions produce these specific changes, so finding them on biopsy is a strong indication for genetic testing. Some biopsies also use special staining to check whether the affected collagen chains are present or absent in the membrane.
Treatment Options
There is no cure for Alport syndrome, but early treatment significantly slows kidney damage. The first-line approach uses medications that block the renin-angiotensin system, a hormonal pathway that regulates blood pressure and fluid balance. These drugs reduce the pressure on the kidneys’ filtering membranes and decrease protein leakage into the urine. Starting this treatment early, even in childhood when blood in the urine is the only sign, can delay kidney failure by years or even decades.
A newer class of medication originally developed for diabetes has shown promise. In an international observational study of 112 patients with Alport syndrome, these drugs reduced protein leakage by more than 30% within the first few months. The reduction held steady at 6 and 12 months of follow-up. Side effects were uncommon: 81% of patients reported none, and only 8% discontinued the medication. A randomized controlled trial is now testing this approach specifically in children and young adults with Alport syndrome.
Kidney Transplant Outcomes
For patients who do progress to kidney failure, transplantation is an effective option, and outcomes are generally better than for many other kidney diseases. In one long-term study, the 20-year patient survival rate after transplant was 70% for Alport syndrome patients, compared to 45% for patients transplanted for other conditions. Median transplant kidney survival was 19.3 years, compared to 12.2 years for other causes of kidney failure. These favorable numbers likely reflect the fact that Alport patients tend to be younger and have fewer other health problems at the time of transplant.
One historical concern was that transplant recipients might develop a dangerous immune reaction against the new kidney. Because their bodies never produced normal type IV collagen, the immune system could theoretically treat the collagen in the donor kidney as foreign and attack it. In practice, this complication appears to be rare. In the same long-term study, no patients developed this reaction, and no evidence of it was found on biopsy specimens from the transplanted kidneys.